- Home
- SLQT vs IGMS Comparison
SLQT vs IGMS Comparison
Compare SLQT & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- IGMS
- Stock Information
- Founded
- SLQT 1999
- IGMS 1993
- Country
- SLQT United States
- IGMS United States
- Employees
- SLQT N/A
- IGMS N/A
- Industry
- SLQT Specialty Insurers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- SLQT Finance
- IGMS Health Care
- Exchange
- SLQT Nasdaq
- IGMS Nasdaq
- Market Cap
- SLQT 476.8M
- IGMS 528.6M
- IPO Year
- SLQT 2020
- IGMS 2019
- Fundamental
- Price
- SLQT $3.35
- IGMS $7.48
- Analyst Decision
- SLQT Hold
- IGMS Buy
- Analyst Count
- SLQT 1
- IGMS 8
- Target Price
- SLQT $4.00
- IGMS $16.25
- AVG Volume (30 Days)
- SLQT 689.3K
- IGMS 213.0K
- Earning Date
- SLQT 02-05-2025
- IGMS 11-08-2024
- Dividend Yield
- SLQT N/A
- IGMS N/A
- EPS Growth
- SLQT N/A
- IGMS N/A
- EPS
- SLQT N/A
- IGMS N/A
- Revenue
- SLQT $1,381,309,000.00
- IGMS $2,918,000.00
- Revenue This Year
- SLQT $12.73
- IGMS $386.95
- Revenue Next Year
- SLQT $14.03
- IGMS N/A
- P/E Ratio
- SLQT N/A
- IGMS N/A
- Revenue Growth
- SLQT 28.72
- IGMS 57.64
- 52 Week Low
- SLQT $1.03
- IGMS $6.17
- 52 Week High
- SLQT $4.46
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- SLQT 69.50
- IGMS 31.94
- Support Level
- SLQT $2.69
- IGMS $7.00
- Resistance Level
- SLQT $2.96
- IGMS $10.80
- Average True Range (ATR)
- SLQT 0.17
- IGMS 1.02
- MACD
- SLQT -0.00
- IGMS -0.10
- Stochastic Oscillator
- SLQT 72.54
- IGMS 10.39
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.